Aesthetic Medical International Holdings Group Limited

DB:3FMA Stock Report

Market Cap: €11.4m

Aesthetic Medical International Holdings Group Valuation

Is 3FMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3FMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3FMA (€0.21) is trading below our estimate of fair value (€1.6)

Significantly Below Fair Value: 3FMA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3FMA?

Key metric: As 3FMA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 3FMA. This is calculated by dividing 3FMA's market cap by their current revenue.
What is 3FMA's PS Ratio?
PS Ratio0.1x
SalesCN¥726.67m
Market CapCN¥86.48m

Price to Sales Ratio vs Peers

How does 3FMA's PS Ratio compare to its peers?

The above table shows the PS ratio for 3FMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.7x
V3V VITA 34
0.9x2.9%€72.2m
UOM AS Latvijas Juras medicinas centrs
0.5xn/a€5.4m
GME Geratherm Medical
1x1.9%€21.0m
MAK Maternus-Kliniken
0.3xn/a€33.6m
3FMA Aesthetic Medical International Holdings Group
0.1xn/a€12.0m

Price-To-Sales vs Peers: 3FMA is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.7x).


Price to Sales Ratio vs Industry

How does 3FMA's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
EIF MedNation
0.1xn/aUS$4.74m
TLIK Arzneiwerk VIDA
0.07xn/aUS$4.64m
No more companies available in this PS range
3FMA 0.1xIndustry Avg. 0.6xNo. of Companies3PS00.40.81.21.62+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 3FMA is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Healthcare industry average (0.7x).


Price to Sales Ratio vs Fair Ratio

What is 3FMA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3FMA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 3FMA's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies